Back to top
more

West Pharmaceutical Services (WST)

(Delayed Data from NYSE)

$238.39 USD

238.39
505,697

-0.87 (-0.36%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $238.35 -0.04 (-0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 19% (46 out of 246)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

COVID Test Demand to Aid Quest Diagnostics (DGX) Q3 Earnings

by Zacks Equity Research

In terms of strategic acquisitions, Quest Diagnostics (DGX) is likely to have secured high returns in Q3 from the acquisition of Mercy's outreach laboratory services business.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Abbott Laboratories, UnitedHealth, Quest, and West Pharmaceutical

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Abbott Laboratories, UnitedHealth, Quest, and West Pharmaceutical

Zacks Equity Research

Growing COVID-19 Testing Demand to Boost Abbott's (ABT) Q3 Earnings

by Zacks Equity Research

Through July to September, Abbott's (ABT) Diagnostic business is likely to have benefited from the significant surge in the new COVID-19 case counts.

Zacks Equity Research

Thermo Fisher (TMO) to Report Q3 Earnings: What's in Store?

by Zacks Equity Research

Thermo Fisher's (TMO) recent launches within Chromatography and Mass Spectrometry like Thermo Scientific Orbitrap IQ-X Tribrid Mass Spectrometer should have contributed to its Q3 top line.

Zacks Equity Research

Why the Earnings Surprise Streak Could Continue for West Pharmaceutical (WST)

by Zacks Equity Research

West Pharmaceutical (WST) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Equity Research

Here's Why You Should Hold on to PerkinElmer (PKI) Stock Now

by Zacks Equity Research

PerkinElmer (PKI) continues to gain momentum from a solid product portfolio and healthy margins. However, forex woes linger.

Zacks Equity Research

Here's Why You Should Retain DENTSPLY SIRONA (XRAY) Now

by Zacks Equity Research

DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, forex woe persists.

Zacks Equity Research

Quest Diagnostics' (DGX) Efforts to Reduce Health Inequities

by Zacks Equity Research

Quest Diagnostics' (DGX) efforts to support AHA will boost innovative solutions like the Scholars programs, hypertension control and COVID-19 rapid response.

Zacks Equity Research

Catalent (CTLT) Expands Presence in Japan Via New Facility

by Zacks Equity Research

Catalent's (CTLT) new site is expected to become a key hub in its Asia-Pacific Clinical Supply Services network by significantly boosting its business.

Zacks Equity Research

Medtronic (MDT) Sees Business Recovery Despite Volume Pressure

by Zacks Equity Research

According to Medtronic (MDT), healthcare systems are better prepared as vaccination rates continue to increase.

Zacks Equity Research

Veeva Systems' (VEEV) eConsent Solution Gets Adopted by Celerion

by Zacks Equity Research

Veeva Systems' (VEEV) solution gets adopted by Celerion in a bid to boost paperless clinical trials.

Zacks Equity Research

Here's Why You Should Retain ResMed (RMD) Stock for Now

by Zacks Equity Research

Investors are optimistic about ResMed (RMD) owing to new product launches in the SDB market and strong sales of mask products.

Zacks Equity Research

Here's Why You Should Add DexCom (DXCM) Stock to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about DexCom (DXCM) owing to its slew of favorable coverage decisions for its G6 CGM System.

Zacks Equity Research

Here's Why You Should Retain Integer Holdings (ITGR) Stock Now

by Zacks Equity Research

Integer Holdings (ITGR) continues to gain traction from portfolio management. However, intense competition is a woe.

Zacks Equity Research

Here's Why You Should Retain LabCorp (LH) Stock For Now

by Zacks Equity Research

Strength in Drug Development business and new strategies to expand into high-growth markets raise optimism for LabCorp (LH).

Zacks Equity Research

Here's Why You Should Retain Merit Medical (MMSI) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Merit Medical (MMSI) owing to its potential in the Peripheral Intervention arm and a strong product portfolio.

Zacks Equity Research

Omnicell (OMCL) Soars to 52-Week High, Time to Cash Out?

by Zacks Equity Research

Omnicell (OMCL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

Here's Why You Should Invest in AmerisourceBergen (ABC) Stock

by Zacks Equity Research

AmerisourceBergen (ABC) continues to gain traction from the robust pharmaceutical segment.

Zacks Equity Research

Here's Why You Should Invest in West Pharmaceutical (WST) Now

by Zacks Equity Research

West Pharmaceutical (WST) continues to gain momentum on the back of strength in Proprietary Products business.

Zacks Equity Research

AMN Healthcare (AMN) Hits 52-Week High: What's Behind It?

by Zacks Equity Research

Investors are optimistic about AMN Healthcare's (AMN) broad array of services.

Zacks Equity Research

Surmodics' (SRDX) Latest Sublime Catheter Expands Patient Pool

by Zacks Equity Research

Surmodics' (SRDX) latest addition is expected to aid in performing more complex interventions which were earlier not possible.

Zacks Equity Research

Dexcom's (DXCM) G6 CGM System Gets Coverage in Manitoba

by Zacks Equity Research

Dexcom's (DXCM) CGM System is expected to simplify diabetes management due to increasing access to the life changing technology.

Zacks Equity Research

Reasons to Hold on to Inari Medical (NARI) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Inari Medical (NARI) owing to its focus on understanding the venous system and its commitment toward patient care.

Zacks Equity Research

Reasons to Hold on to Veeva Systems (VEEV) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Veeva Systems (VEEV) on its slew of product launches and robust product adoptions.

Zacks Equity Research

Here's Why You Should Invest in Patterson Companies (PDCO) Stock

by Zacks Equity Research

Patterson Companies (PDCO) continues to benefit from strength in Animal Health business and dental business.